Interestingly, preclinical studies have shown that the combined targeting of CD37 and CD20 with 177Lu-lilotomab satetraxetan and rituximab can improve the therapeutic outcome of NHL [18]. Here, CD37 is linked to non-Hodgkin lymphoma.